INVADERS
Financiado
Mucus Penetrating Microbiota Characterization Mechanism and Therapeutic in Met...
Mucus Penetrating Microbiota Characterization Mechanism and Therapeutic in Metabolic Disease
Mucus-Penetrating Microbiota: Characterization, Mechanism and Therapeutic in Metabolic Disease
Humanity is facing an epidemic of inter-related metabolic disorders, including obesity, insulin resistance, hyperglycemia, hyperlipide...
Mucus-Penetrating Microbiota: Characterization, Mechanism and Therapeutic in Metabolic Disease
Humanity is facing an epidemic of inter-related metabolic disorders, including obesity, insulin resistance, hyperglycemia, hyperlipidemia, and hepatic steatosis, that altogether have major impact on the promotion of cardiovascular diseases. The increasing incidence of these complex metabolic disorders and their highly morbid, chronic and costly downstream diseases threatens to overwhelm the world’s health care systems and economies, making it a top public health priority in dire need of investigation.
The intestinal tract is inhabited by a large and diverse community of bacteria, collectively referred to as the intestinal microbiota. When stably maintained at an appropriately safe distance from the epithelial cell monolayer, the microbiota provides important benefits to its host. However, disturbance of the microbiota-host relationship, promoted by genetic or non-genetic factors, can alter intestinal homeostasis and drive chronic low-grade intestinal inflammation, ultimately leading to metabolic abnormalities. We previously reported that a ubiquitous class of food additives, emulsifiers, detrimentally impact the microbiota resulting in its encroachment into the mucus layer that associated with low-grade inflammation and development of metabolic disorders.
The central goal of this proposal is to investigate the hypothesis that bacteria that penetrate the inner part of the mucus layer, referred as invaders, promote development of metabolic alterations.
We herein propose to identify mucus-invaders, in preclinical models and clinical conditions, and investigate mechanisms by which they promote inflammatory and metabolic abnormalities. Furthermore, we propose to define original approaches to modulate the intestinal microbiota in order to counteract microbiota encroachment and protect against associated metabolic abnormalities.
ver más
Duración del proyecto: 63 meses
Fecha Inicio: 2019-06-19
Fecha Fin: 2024-09-30
Fecha Fin: 2024-09-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2018-STG:
ERC Starting Grant
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
244.04K€ |
Participante